Inhaled CNS Drugs for central nervous system disease treatment

Delivering drugs to the central nervous system presents unique challenges. But, drug developers and researchers have discovered that delivering CNS therapeutic drugs via inhalation mitigates several of these issues. The accessibility and vascular structure of the nose make it an attractive route for delivering both small molecule drugs and biologics across the blood-brain barrier to the CNS. Pulmonary delivery to the deep lung can have favorable pharmacokinetics. And inhaled delivery offers the potential for faster onset of action and less frequent dosing relative to oral drugs. These potential advantages have spurred activity in inhaled CNS therapeutics for a range of disorders. As aging population demographics and managed care initiatives drive growth in home health care and self-administration of drug therapies, inhaled medicine is increasingly being viewed as patient-friendly and cost-effective. Our analysis indicated that inhaled CNS administration is well positioned to take advantage of these trends and evolve into a significant factor in the future of pharmaceutical development and commercialization of CNS therapeutic drugs.

Publication Date: May 2009

Table of Contents

Executive Summary

Drug Delivery Market Dynamics

The Trend toward Self-Administration

Demographic Shifts

Managed Care Initiatives

Growth in Home Healthcare

Technology Market Drivers

CNS Therapeutic Sector Assessment

Alzheimer’s

ADHD

Autism

Dementia

Depression

Epilepsy

Migraine

Multiple Sclerosis

Nausea

Pain Management

Parkinson’s

Schizophrenia

Sleeping disorders

Stroke

Inhaled Drug Development Factors

Absorption

Bioavailability

Device Design Parameters

Nasal Delivery Pharmacokinetics

Nasal Device Characteristics

Pulmonary Delivery Pharmacokinetics

Pulmonary Device Characteristics

Market Factors

FDA Regulations

Clinical Trials

Impact of Generics

FDA-Approved Inhaled CNS Drug Products

Butorphanol

Imitrex

Migranal

Zomig

Development-Stage Inhaled CNS Drug Products

Apomorphine

Carbetocin

Dronabinol

Dihydroergotomine

Emitasol

Fentanyl

Ketamine

Loxapine

Morphine

Prochlorperazine

Rylomine

Triazolam

Segment Data, Analysis and Forecasts

Sector Participant Company Profiles

About Our Reports

Our reports are carefully researched and written to provide timely and insightful analysis of key factors and developments shaping the commercial marketplace. The focused nature of our publications is designed to allow readers to identify emerging demand and growth opportunities in selected markets. Numerous charts, tables and graphs complement the text, with evaluations and assessments of current and probable future market developments, technology issues and business factors - information necessary to compete effectively in the global marketplace.